Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ICER
Pharma
Pfizer's ATTR drug needs hefty discount, says ICER draft report
ICER also conducted a preliminary analysis of Alnylam’s Amvuttra, which recently reported a positive phase 3 readout in ATTR-CM.
Angus Liu
Jul 18, 2024 4:37pm
Verona's price for COPD drug far exceeds ICER's valuation
Jul 16, 2024 2:31pm
ICER chief lays out requirement for more IRA involvement
Jan 30, 2024 3:15pm
AbbVie's Humira, J&J's Darzalex top ICER's annual price-hike list
Dec 11, 2023 11:26am
Vertex's pricing won't affect bluebird's strategy on lovo-cel
Nov 7, 2023 3:20pm
ICER weighs in on Eliquis, Xarelto price negotiations at CMS
Oct 2, 2023 2:42pm
